相关实验视频

Updated: Jun 7, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

在5-阿扎丁骨髓质疏松症综合征前后样本的分子分析确定了反应的预测因子

Mónica Del Rey González^1,2, Sohini Chakraborty², Jesús María Hernández-Sánchez¹

¹Institute for Biomedical Research of Salamanca (IBSAL), Institute of Cancer Molecular and Cellular Biology (IBMCC)-Centro de Investigación del Cáncer, Universidad de Salamanca, Salamanca, Spain.

Frontiers in oncology

|October 8, 2024

概括

难以预测骨髓质疏松症候群 (MDS) 中对5-阿扎西丁 (AZA) 治疗的反应. 这项研究开发了一种使用CD34+细胞的新转录分类器,用于预测MDS患者的AZA反应和存活率.

科学领域:

血液学血液学血液学
分子生物学分子生物学
癌症研究癌症研究

背景情况:

5 - 亚西丁 (AZA) 改善了高风险骨髓发育综合征 (MDS) 的存活率.
预测患者对AZA治疗的反应和生存率仍然是一个临床挑战.
了解AZA后的造血干细胞/原生细胞 (HSPC) 的分子变化至关重要.

研究的目的:

在MDS患者AZA治疗前和后分析CD34+HSPC中的突变和转录概况.
为了确定能够预测AZA治疗反应的分子标记.
开发AZA反应和生存的预测分类器.

主要方法:

从MDS患者的CD34+HSPC中分析突变和转录资料.
对AZA治疗的响应者和不响应者之间的个人资料比较.
开发和验证一个转录分类器来预测AZA反应.

主要成果:

在响应者中,AZA治疗更有效地降低了突变负担.
受访者在治疗前显示氧化酸化,MYC目标和mTORC1信号通路的丰富.
一个新的转录分类器预测了AZA反应和生存,超过了现有的签名.

结论:

在MDS HSPCs中,AZA治疗会诱导明显的分子变化.
预测性转录分类器可以帮助确定AZA治疗反应和患者存活率.
该工具可以指导MDS患者在治疗开始前个性化治疗策略.

关键词:

基因表达的基因表达方式造血干细胞/原始细胞 (HSPCs) 是一种细胞.突变是发生在突变中的突变.骨髓分裂性综合征 (MDS) 是一种疾病.患者的生存率患者的生存率预后预后预后

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...